188 related articles for article (PubMed ID: 31505928)
1. Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.
Agrawal N; Rowe J; Lan J; Yu Q; Hrycyna CA; Chmielewski J
J Med Chem; 2020 Mar; 63(5):2131-2138. PubMed ID: 31505928
[TBL] [Abstract][Full Text] [Related]
2. Tools for eradicating HIV in the brain: prodrug dimeric inhibitors of P-gp.
Chmielewski J; Hrycyna C
Ther Deliv; 2012 Jun; 3(6):689-92. PubMed ID: 22838065
[TBL] [Abstract][Full Text] [Related]
3. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.
Namanja HA; Emmert D; Davis DA; Campos C; Miller DS; Hrycyna CA; Chmielewski J
J Am Chem Soc; 2012 Feb; 134(6):2976-80. PubMed ID: 21866921
[TBL] [Abstract][Full Text] [Related]
4. Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir.
Roy U; Bulot C; Honer zu Bentrup K; Mondal D
PLoS One; 2013; 8(10):e75374. PubMed ID: 24098380
[TBL] [Abstract][Full Text] [Related]
5. Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of the Atypical Antipsychotic Agent Paliperidone in a Model of the Blood-Brain Barrier.
Bohn K; Lange A; Chmielewski J; Hrycyna CA
Mol Pharm; 2017 Apr; 14(4):1107-1119. PubMed ID: 28264565
[TBL] [Abstract][Full Text] [Related]
6. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.
Leibrand CR; Paris JJ; Jones AM; Masuda QN; Halquist MS; Kim WK; Knapp PE; Kashuba ADM; Hauser KF; McRae M
J Neurovirol; 2019 Aug; 25(4):560-577. PubMed ID: 31102185
[TBL] [Abstract][Full Text] [Related]
8. P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
Sankatsing SU; Beijnen JH; Schinkel AH; Lange JM; Prins JM
Antimicrob Agents Chemother; 2004 Apr; 48(4):1073-81. PubMed ID: 15047504
[No Abstract] [Full Text] [Related]
9. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
Huisman MT; Smit JW; Schinkel AH
AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499
[No Abstract] [Full Text] [Related]
10. Actin filament-associated protein 1 (AFAP-1) is a key mediator in inflammatory signaling-induced rapid attenuation of intrinsic P-gp function in human brain capillary endothelial cells.
Hoshi Y; Uchida Y; Tachikawa M; Ohtsuki S; Terasaki T
J Neurochem; 2017 Apr; 141(2):247-262. PubMed ID: 28112407
[TBL] [Abstract][Full Text] [Related]
11. Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function
Patel S; Leibrand CR; Palasuberniam P; Couraud PO; Weksler B; Jahr FM; McClay JL; Hauser KF; McRae M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893794
[TBL] [Abstract][Full Text] [Related]
12. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins.
Gimenez F; Fernandez C; Mabondzo A
J Acquir Immune Defic Syndr; 2004 Jun; 36(2):649-58. PubMed ID: 15167283
[TBL] [Abstract][Full Text] [Related]
13. Cellular factors involved in the induction of resistance of HIV to antiretroviral agents.
Turriziani O; Antonelli G; Dianzani F
Int J Antimicrob Agents; 2000 Nov; 16(3):353-6. PubMed ID: 11091062
[TBL] [Abstract][Full Text] [Related]
14. Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs.
Kock A; Zuwala K; Smith AA; Ruiz-Sanchis P; Wohl BM; Tolstrup M; Zelikin AN
Chem Commun (Camb); 2014 Dec; 50(93):14498-500. PubMed ID: 25285337
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches for designing 5'-O-ester prodrugs of 3'-azido-2', 3'-dideoxythymidine (AZT).
Parang K; Wiebe LI; Knaus EE
Curr Med Chem; 2000 Oct; 7(10):995-1039. PubMed ID: 10911016
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
17. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
[TBL] [Abstract][Full Text] [Related]
18. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibitors of the human blood-brain barrier drug efflux transporters P-glycoprotein and ABCG2 based on the antiviral azidothymidine.
Namanja-Magliano HA; Bohn K; Agrawal N; Willoughby ME; Hrycyna CA; Chmielewski J
Bioorg Med Chem; 2017 Oct; 25(19):5128-5132. PubMed ID: 28712845
[TBL] [Abstract][Full Text] [Related]
20. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.
Savolainen J; Edwards JE; Morgan ME; McNamara PJ; Anderson BD
Drug Metab Dispos; 2002 May; 30(5):479-82. PubMed ID: 11950774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
